Key facts
- It has raised $3.1M; the latest was Early Stage VC ($2.6M) in Apr 2026.
- Notable investors include Mission BioCapital, ACS BrightEdge, Impact Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Deck Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Deck Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Deck Bio
Developer of cell receptor therapeutics targeting highly expressed cancer specific peptide MHCs, intended to develop a single drug to increase response rates and reduce drug resistance for cancer patients. The company's platform is developing a proprietary technology to enable multi target recognition with a single drug, supporting higher response rates and reduced treatment resistance, enabling oncology researchers and biopharmaceutical companies seeking new immuno oncology approaches to advance targeted cancer therapies for a broader patient population.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2023
- Employees
- 2
- Website
- deck.bio/
- Ownership
- Privately Held (backing)
Deck Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Deck Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Deck Bio in its N-PORT filings yet. We sweep new filings monthly.